News

Filter

Current filters:

IndiaGilead Sciences

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

26-01-2015

US biotech major Gilead Sciences has expanded its hepatitis C generic licensing agreements to include…

Anti-viralsBiotechnologyGenericsGilead SciencesIndiaLicensingSovaldiUSA

Big pharma increasingly collaborating with Indian companies

Big pharma increasingly collaborating with Indian companies

26-11-2014

Even as multinational pharma majors are looking for new ways to squeeze costs along the whole value chain,…

Gilead SciencesIndiaLicensingMarkets & MarketingMergers & AcquisitionsPharmaceuticalRussia

Medicines Patent Pool broadens collaboration with Gilead Sciences

24-07-2014

The Medicines Patent Pool (MPP) has entered into a new licensing agreement with US biotech firm Gilead…

Anti-viralsChinaGenericsGilead SciencesIndiaLicensingProductiontenofovir alafenamide

India/USA trade dispute could impact AIDS treatment programs

10-03-2014

The trade dispute over intellectual property rights between the USA and India is set to derail the distribution…

Anti-viralsCiplaGenericsGilead SciencesGlaxoSmithKlineIndiaPatentsPricingUSA

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

Gilead to offer hep C drug sofosbuvir at greatly-reduced price in developing countries

07-02-2014

US biotech Gilead Sciences has indicated it would charge $2,000 per 24 week treatment course for the…

Anti-viralsBiotechnologyGilead SciencesGlobalIndiaPricingsofosbuvirSovaldi

Mylan gets exclusive rights to distribute Gilead branded drugs in India

Mylan gets exclusive rights to distribute Gilead branded drugs in India

31-01-2014

US generics major Mylan says its India-based subsidiary has been named) exclusive branded medicines business…

AmbisomeAnti-viralsAsia-PacificBiotechnologyGilead SciencesIndiaMarkets & MarketingMylan LaboratoriesStribildTruvadaViread

Back to top